Source: Adenosine Therapeutics, LLC submitted to NRP
A2A ADENOSINE RECEPTORS AND EQUINE SEPSIS
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
COMPLETE
Funding Source
SMALL BUSINESS GRANT
Reporting Frequency
Annual
Accession No.
0196506
Grant No.
2003-33610-13038
Cumulative Award Amt.
$75,000.00
Proposal No.
2003-00471
Multistate No.
(N/A)
Project Start Date
May 15, 2003
Project End Date
Nov 14, 2004
Grant Year
2003
Program Code
[8.3]- (N/A)
Recipient Organization
Adenosine Therapeutics, LLC
(N/A)
Charlottesville,VA 22911
Performing Department
(N/A)
Non Technical Summary
This is a phase I SBIR proposal by Adenosine Therapeutics for 6 months of support to synthesize and evaluate novel compounds as agonists of equine A2A adenosine receptors. Some of these compounds have been found to be very effective in reducing rodent mortality form endotoxin or from E. coli-induced sepsis. Circulating endotoxin (lipopolysaccharide) is correlated with the probability of death in horses of all ages (colic in adult horses; septicemia in neonates). These studies have the potential of producing a new therapy of horse sepsis and colic that are devastating equine diseases. Our goal is to develop new therapies for the treatment of equine sepsis and colic. Such new therapies have excellent commercial potential since these diseases occur in tens of thousands of horses annually and these animals have a poor prognosis. Preliminary studies in rodents indicate that this new type of therapy is highly effective in reducing the severity of septic inflammation and drastically reduces the frequency of mortality.
Animal Health Component
100%
Research Effort Categories
Basic
(N/A)
Applied
100%
Developmental
(N/A)
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
3113810116020%
3113810200080%
Knowledge Area
311 - Animal Diseases;

Subject Of Investigation
3810 - Horses, ponies, and mules;

Field Of Science
1160 - Pathology; 2000 - Chemistry;
Goals / Objectives
This is a phase I SBIR proposal by Adenosine Therapeutics for 6 months of support to synthesize and evaluate novel compounds as agonists of equine A2A adenosine receptors.
Project Methods
At the University of Georgia, Tom Murray, PhD has recently succeeded in cloning the equine A2A adenosine receptor, and James Moore, PhD is a leading authority on the study of equine sepsis. This proposal is a joint venture between Adenosine Therapeutics and the University of Georgia to synthesize and evaluate A2A agonist compounds for (1) binding to recombinant equine A2A adenosine receptors; (2) function as assessed by their ability to inhibit TNF release from equine monocytes; and (3) duration of action as assessed by persistence of vasocillator action in rats. An optimal compound based on high potency and long duration of action will be selected as a therapeutic candidate and evaluated for its ability to reduce markers of inflammation in horses treated with endotoxin.